These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25792732)

  • 21. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases.
    Bulani Y; Sharma SS
    Curr Pharm Des; 2015; 21(30):4392-9. PubMed ID: 26471318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
    Leonardi S; Becker RC
    Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving long-term outcome after myocardial infarction.
    James S; Held C
    Lancet; 2012 Oct; 380(9850):1290-1. PubMed ID: 22932713
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
    Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
    Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
    Serebruany VL; Fortmann SD; Rao SV; Tanguay JF; Lordkipanidze M; Hanley DF; Can M; Kim MH; Marciniak TA
    Thromb Haemost; 2016 May; 115(5):905-10. PubMed ID: 26887783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
    Noguchi D; Kuriyama N; Ito T; Fujii T; Kato H; Mizuno S; Sakurai H; Isaji S
    J Surg Res; 2020 Feb; 246():568-583. PubMed ID: 31653415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells.
    Riewald M; Petrovan RJ; Donner A; Ruf W
    J Endotoxin Res; 2003; 9(5):317-21. PubMed ID: 14577849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
    Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
    Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteinase-activated receptors (PARs) as targets for antiplatelet therapy.
    Cunningham M; McIntosh K; Bushell T; Sloan G; Plevin R
    Biochem Soc Trans; 2016 Apr; 44(2):606-12. PubMed ID: 27068977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4.
    Wang H; Ricklin D; Lambris JD
    Proc Natl Acad Sci U S A; 2017 Oct; 114(41):10948-10953. PubMed ID: 28973891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.